GlaxoSmithKline R&D Expense: 1.59B
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
GSK R&D Expense Rankings
| Overall | 0th percentile | 1865 of 1873 |
| Sector | 1st percentile | 425 of 430 in Healthcare |
| Industry | 19th percentile | 20 of 25 in Drug Manufacturers - Major |
GSK R&D Expense Range, Past 5 Years
| Minimum | 1.00B | Mar 2003 |
| Maximum | 1.86B | Dec 2006 |
| Average |
About R&D Expense
R&D expenses are a line item from many companies' income statements.
R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.
Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.
An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
Learn More
You may also be interested in these GSK related companies
GSK News
Interesting to see $GSK boasting about how it is repatriates its cash from European operations so fast these days. Probably a wise move.
about 5 days ago by bradloncar
about 5 days ago by bradloncar
GlaxoSmithKline plc's CEO Discusses Q4 2011 Results - Earnings Call Transcript
Feb 07, 3:30PM Seeking Alpha
Feb 07, 3:30PM Seeking Alpha
Siemens Forms New Companion Diagnostics Partnerships with ViiV Healthcare and Tocagen
Feb 07, 11:33AM PR Newswire
Feb 07, 11:33AM PR Newswire
$GSK IR on Twitter. Smart example. "GSK to announce 2011 year-end results [today] at noon GMT. We'll be using the hashtag #GSKFY11"
about 6 days ago by BHSMITH
about 6 days ago by BHSMITH
Anacor Pharmaceuticals Down 14.4% After GlaxoSmithKline Pauses Ongoing Trials
Feb 06, 9:20AM Benzinga
Feb 06, 9:20AM Benzinga
Glaxo (GSK) Halts Enrollment in GSK '052 Phase 2b Following Recent Discovery (ANAC)
Feb 06, 8:31AM Street Insider
Feb 06, 8:31AM Street Insider
$ANAC reports partner GlaxoSmithKline $GSK has voluntarily paused enrollment of ongoing GSK '052 Phase 1, 2 Clinical Trials; ANAC halted
about 7 days ago by Street_Insider
about 7 days ago by Street_Insider
Drastic day for healthcare, esp. with pneumonia-deaths in clinical trials! http://stks.co/1qHP $THRX $BMY $GSK $INHX $IDIX
about 34 days ago by juliat333
about 34 days ago by juliat333
$GSK http://stks.co/1oDf $GSK looking intersting here, looking @ Feb 46 call or ITM 45's
about 37 days ago by _TheBlackSwan_
about 37 days ago by _TheBlackSwan_
RT @BloombergNews Drug approvals hit a seven-year high | http://stks.co/1n8c $GSK $JNJ
about 38 days ago by brittpierpoint
about 38 days ago by brittpierpoint
@Dostoevsky $HGSI has a few other drugs in development, in addition to a long-term relationship with $GSK
about 53 days ago by samlee22
about 53 days ago by samlee22
$GSK to sell 17 OTC brands in North America to $PBH for $660M; PBH shares up 7.8% pre-open
about 55 days ago by Street_Insider
about 55 days ago by Street_Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| GSK | 44.75 | -0.31 | -0.69% | 114.07B |
| IO | 8.05 | -0.46 | -5.41% | 1.25B |
| TU | 53.92 | -0.90 | -1.64% | 8.07B |
| LLNW | 3.98 | -0.12 | -2.81% | 453.32M |
| HEB | 0.37 | 0.04 | 10.45% | 50.13M |
| ATPG | 6.69 | -0.14 | -2.05% | 345.34M |
| NWSA | 19.18 | -0.04 | -0.18% | 33.02B |
| ASUR | 6.77 | 0.02 | 0.30% | 20.92M |
| ACAS | 8.69 | 0.15 | 1.76% | 3.00B |
| HBAN | 5.91 | -0.12 | -2.07% | 5.10B |
